Comparative Pharmacology
Head-to-head clinical analysis: EOHILIA versus SOLU CORTEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EOHILIA versus SOLU CORTEF.
EOHILIA vs SOLU-CORTEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
Solu-Cortef (hydrocortisone sodium succinate) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators, including prostaglandins and leukotrienes. It also inhibits immune cell migration and activation.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
100-1000 mg intravenous (IV) or intramuscular (IM), then 100-500 mg IV or IM every 2-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Terminal elimination half-life: 1.5-2 hours (hydrocortisone); clinical duration of action is longer due to genomic effects (6-8 hours).
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Renal: ~80% as metabolites (mainly 17-hydroxycorticosteroids) and <5% unchanged. Biliary/fecal: minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid